Intratumoral Cancer Therapies Market Set to Grow with a Remarkable CAGR of 31.3% Through 2034, Driven by Revolutionary Advances in Oncolytic Viral Therapy Pipeline | DelveInsight

The intratumoral cancer therapies market is undergoing rapid expansion, driven by rising cancer incidence, breakthrough oncolytic viral therapies, and innovative immunotherapy approaches from key pharmaceutical players including Nanobiotix, Sirnaomics, Apexigen, Replimune, Merck, OncoSec Medical, Intensity Therapeutics, DNAtrix, Treovir, Philogen, Regeneron, Pfizer, BMS, Roche, Sanofi, Boehringer Ingelheim, Daiichi Sankyo, and others.
DelveInsight's "Intratumoral Cancer Therapies Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers an in-depth understanding of the intratumoral cancer therapies market, historical and forecasted epidemiology, as well as market trends across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. The report comprehensively evaluates the current treatment practices, emerging drugs, market share of individual therapies, and intratumoral cancer therapies market forecasts through 2034, providing crucial insights for stakeholders in the oncology therapeutic area.

According to DelveInsight's analysis, the intratumoral cancer therapies market is projected to witness exponential growth at a remarkable CAGR of 31.3% during the study cperiod 2020-2034 in the 7MM, driven by the anticipated approval of novel therapies with potential to transform "cold tumors" into "hot tumors," thereby facilitating immune system targeting of cancer cells. Furthermore, the United States is expected to capture the maximum chunk of the intratumoral cancer therapy market share.

Download the Intratumoral Cancer Therapies Market report to understand which factors are driving the therapeutic market @ Intratumoral Cancer Therapies Market Trends [https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

According to DelveInsight's estimates, the total intratumoral cancer patient pool across 7MM in 2024 were 3.3 million, which is expected to grow significantly during the forecast period.

The DelveInsight report categorizes intratumoral cancer therapies into several segments, including total cases of selected indications, indication-wise target patient pool of intra-tumoral cancer therapies and indication-wise treated cases of intra-tumoral cancer therapies.

Discover evolving trends in the Intratumoral Cancer Therapies patient pool forecasts @ Intratumoral Cancer Therapies Epidemiology Analysis [https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Intra-tumoral immunotherapy is gaining momentum as a targeted cancer treatment approach, offering localized immune activation with reduced systemic side effects. The first approved therapy in this space, Amgen's IMLYGIC (T-Vec), received US FDA approval for unresectable melanoma and later European approval in 2015. However, despite its innovative approach, IMLYGIC struggled commercially due to limited overall survival benefits and competition from immune checkpoint inhibitors. Other advances include Nanobiotix's HENSIFY (NBTXR3), approved in Europe for soft tissue sarcoma, and Japan's conditional approval of DELYTACT (G47) for malignant glioma, marking a significant step forward in oncolytic viral therapies.

According to the DelveInsight report, the intratumoral cancer therapies pipeline is rapidly expanding, with several promising candidates advancing toward regulatory milestones. Replimune's lead candidate RP1 (vusolimogene oderparepvec), developed using a proprietary Herpes Simplex Virus (HSV) platform, received FDA Breakthrough Therapy Designation in November 2024 with combination with Bristol Myers Squibb's nivolumab for advanced melanoma. Philogen, in collaboration with Sun Pharmaceutical, achieved EMA validation of its Marketing Authorization Application (MAA) in July 2024 for Nidlegy (L19IL2 + L19TNF), a novel skin cancer therapy. Candel Therapeutics is preparing for a Biologics License Application (BLA) submission by Q4 2026 for CAN-2409, an adenoviral immunotherapy targeting prostate cancer.

Other key players driving innovation include Lytix Biopharma and Verrica Pharmaceuticals with LTX-315 (VP-315), CEL-SCI with MULTIKINE, Highlight Therapeutics with BO-112, Cytovation ASA with CY-101, Intensity Therapeutics with INT230-6, Ascendis Pharma with TransCon IL-2 , Treovir and Matica Biotechnology with G207, QBiotics with Tigilanol tiglate, NanOlogy with NanoPac, EpicentRx with AdAPT-001, and Medicenna Therapeutics with Bizaxofusp (MDNA55). As these next-generation therapies advance, they are set to revolutionize the intra-tumoral cancer treatment landscape, offering novel therapeutic options and setting new standards in oncology care.

In early 2025, several key developments underscored the growing momentum in the intratumoral cancer therapies market. In March, Nanobiotix (EPA:NANO) announced topline results from the dose-escalation portion of a Phase I trial evaluating JNJ-1900 (NBTXR3), activated by radiation therapy, as a second-line or later treatment for locally advanced NSCLC in patients eligible for re-irradiation. That same month, Nanobiotix amended its global licensing agreement with Janssen Pharmaceutical, removing its funding obligation for the NANORAY-312 trial and waiving select future milestone payments from Johnson & Johnson, while preserving the potential for significant future revenue.

Also in March, Candel Therapeutics (NASDAQ:CADL) entered a strategic commercial partnership with IDEA Pharma, which will support the development and commercialization of CAN-2409. In January 2025, Lokon Pharma AB received Fast Track Designation (FTD) from the FDA for LOAd703, its candidate for the treatment of pancreatic cancer. Around the same time, Intensity Therapeutics (NASDAQ:INTS) announced that its Data Monitoring Committee (DMC) recommended the continuation of its Phase III sarcoma trial (INVINCIBLE-3) evaluating INT230-6, based on favorable data from the July to December

Discover recent advancements in the Intratumoral Cancer Therapies treatment landscape @ Intratumoral Cancer Therapies Recent Developments [https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The intratumoral cancer therapies market is highly competitive, with major players including Nanobiotix (EPA:NANO), Sirnaomics (HKEX:2257), Apexigen (NASDAQ:APGN), Replimune (NASDAQ:REPL), Merck & Co (NYSE:MRK), Highlight Therapeutics, OncoSec Medical (NASDAQ:ONCS), Intensity Therapeutics (NASDAQ:INTS), DNAtrix, Treovir, Philogen, Lokon Pharma AB, Regeneron (NASDAQ:REGN), Istari Oncology, Pfizer (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Biogen (NASDAQ:BIIB), Immunovative Therapeutics, Idera Pharmaceuticals, Roche (SWX:ROG), Sanofi (EPA:SAN), Boehringer Ingelheim, and Daiichi Sankyo (TYO:4568), all advancing diverse therapeutic approaches through robust R&D and strategic collaborations.

Looking ahead, the intratumoral cancer therapies market is expected to witness continued innovation driven by advancements in early detection technologies, integration of artificial intelligence in cancer diagnosis, and personalized medicine approaches. The rising incidence of cancer, with over 1.95 million new cases reported in 2023, continues to fuel market growth. Emerging therapies focusing on novel mechanisms, including oncolytic viruses, immunomodulators, and gene-based approaches, hold promise for addressing unmet medical needs [https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr] and transforming the treatment landscape.

DelveInsight's analysis underscores that despite current therapeutic limitations, substantial opportunities remain for developing more effective, targeted treatment options that can achieve durable responses and improved overall survival for cancer patients worldwide. As research accelerates and regulatory frameworks evolve, the intratumoral cancer therapies market is positioned for remarkable expansion and therapeutic breakthroughs through 2034.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Intratumoral Cancer Therapies Market Overview at a Glance

5. Epidemiology and Market Forecast Methodology

6. Key Events

7. Intratumoral Cancer Therapies Background and Overview

8. Intratumoral Cancer Therapies Treatment

9. Intratumoral Cancer Therapies Epidemiology and Patient Population in the 7MM

10. Intratumoral Cancer Therapies Patient Journey

11. Intratumoral Cancer Therapies Marketed Drug

12. Intratumoral Cancer Therapies Emerging Drugs

13. Intratumoral Cancer Therapies: 7MM Analysis

14. Unmet needs

15. SWOT Analysis

16. KOL Views

17. Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=intratumoral-cancer-therapies-market-set-to-grow-with-a-remarkable-cagr-of-313-through-2034-driven-by-revolutionary-advances-in-oncolytic-viral-therapy-pipeline-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.